Heart drug may alter sleep medication levels in the body
NCT ID NCT06671470
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study examines whether ticagrelor, a heart medication, changes how the body absorbs and processes YZJ-1139, an experimental insomnia treatment. Healthy volunteers aged 18 to 45 will take YZJ-1139 alone and then with ticagrelor to compare drug levels and safety. The goal is to understand potential interactions before the sleep drug is used in people who also need heart medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YZJ-1139 and ticagrelor
- What this could lead to
- If successful, this could help determine safe dosing when YZJ-1139 is taken with ticagrelor.
- What could go wrong
- This is an early-phase drug interaction study in healthy people, not patients with insomnia. Results may not predict real-world use or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSOMNIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shulan (Hangzhou) Hospital
Huangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light therapy during sleep may offer a Drug-Free path to better rest
- Mind over bladder: can sleep training curb nighttime urges?
- Can an ancient herbal formula unlock better sleep and weight loss?
- Could a simple sleep guide ease insomnia in lung disease?
- Digital sleep coaching for seniors: a new hope for insomnia?
- Fixing sleep, fortifying hearts: a new trial tests the link